Datapoint: Actemra Granted EUA for Use in COVID Patients

The FDA last week granted Roche’s Actemra an emergency use authorization to treat both adult and juvenile patients hospitalized with COVID-19. The arthritis drug was previously approved for compassionate use, but can now be administered to COVID patients who require oxygen support, in tandem with corticosteroids. For the treatment of rheumatoid arthritis, the intravenous form of Actemra holds covered or better status for 93% of all insured lives under the medical benefit.

SOURCE: MMIT Analytics, as of 6/28/21

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
November 24

Datapoint: Keytruda Scores Major Kidney Cancer Nod

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
November 23

Datapoint: Zing Health Acquires Lasso Healthcare

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
November 22

Datapoint: Paramount Loses Ohio Medicaid Battle

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today